Literature DB >> 7013975

Use of bacterial neutral protease for disaggregation of mouse tumours and multicellular tumor spheroids.

P R Twentyman, J M Yuhas.   

Abstract

A bacterial neutral protease (from Bacillus Polymixa) has been used to disaggregate both solid mouse tumours and multicellular tumour spheroids. The cell yields obtained were much higher than those obtained using trypsin whilst the plating efficiency of the resultant single cells were comparable. The use of this neutral protease is simple, inexpensive and highly efficient.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7013975     DOI: 10.1016/0304-3835(80)90091-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Improved assay of stromal injury based on the number of tumour cells that can be supported by irradiated flank skin.

Authors:  M Penhaligon; R S Camplejohn
Journal:  Br J Cancer Suppl       Date:  1986

2.  Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

3.  The response of tumour cells to radiation and cytotoxic drugs--a comparison of clonogenic and isotope uptake assays.

Authors:  P R Twentyman; G A Walls; K A Wright
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

4.  Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.

Authors:  P Twentyman; P Workman
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

5.  Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation.

Authors:  D W Siemann; E M Lord; P C Keng; K T Wheeler
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

6.  Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain.

Authors:  D J Honess; N M Bleehen
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.